HOME >> BIOLOGY >> NEWS
Combating blindness is vision of UT, ORNL project

OAK RIDGE, Tenn., Feb. 9, 2005 Millions of people at risk of becoming blind could one day be helped by an Oak Ridge National Laboratory technology originally intended to understand semiconductor defects.

The project takes advantage of the Department of Energy lab's proprietary content-based image retrieval technology, which is a method for sorting and finding visually similar images in large databases. Manufacturers of semiconductors have found this technology highly effective for rapidly scanning hundreds of thousands of tiny semiconductors to learn quickly about problems with manufacturing processes.

"We're adapting a proven technology and combining it with new image gathering and analysis tools to help create a database to assist in the diagnosis and treatment of blinding eye diseases such as diabetic retinopathy, glaucoma and age-related macular degeneration," said project co-leader Ken Tobin of ORNL's Engineering Science & Technology Division.

Diabetic retinopathy alone will affect 239 million people worldwide by 2010, according to Tobin, who noted that this number will have doubled since 1994.

Partnering with ORNL is Edward Chaum, an ophthalmologist and Plough Foundation professor of retinal diseases at the University of Tennessee Health Science Center in Memphis.

Researchers plan to use digital retinal photography and optical coherence tomography -- a technique for examining living tissue non-invasively -- to image and quantify specific disease-based changes in the retina. They will develop an extensive image database of known retinal disease states for clinical validation studies.

Institutional Review Board approval was secured to enable Tobin and ORNL colleagues Tom Karnowski and Priya Govindasamy to assemble a database of thousands of fluorescein angiography and optical coherence tomography images representing hundreds of diagnosed human patients and retinal diseases.

"The dataset provided by Dr. Cha
'"/>

Contact: Ron Walli
wallira@ornl.gov
865-576-0226
DOE/Oak Ridge National Laboratory
9-Feb-2005


Page: 1 2

Related biology news :

1. Combating anthrax: Results of study published this month as researchers look for a better vaccine
2. Combating antibiotic resistance
3. Research team enlightens the reasons for severe blindness
4. Study identifies new gene therapy tools for inherited blindness
5. Gene variant increases risk of blindness
6. Penn researchers report that gene therapy awakens the brain despite blindness from birth
7. Lucky 13 as new gene discovery offers further hope for childhood blindness
8. Gene therapy for blindness clears hurdle in mice
9. Transport interrupted -- Texas A&M biologists trace cause of early blindness to tissue defect
10. Gene therapy for inherited childhood blindness tested in mice
11. Gene therapy for chicken model of childhood blindness

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Combating blindness vision ORNL project

(Date:8/19/2015)...  VOXX International Corporation (Nasdaq: VOXX ) ... Definitive Agreement to purchase the assets, inclusive of ... EyeLock through an acquiring entity.  Upon consummation of ... in the acquiring entity. The closing of the ...  Expanding on its existing supply chain and distribution ...
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2MedNet Solutions Experiences Explosive Corporate Growth 2
(Date:9/2/2015)... -- Biovista Inc. is glad to announce ... science challenge, a global competition hosted by the Rare ... the latest life science innovations and technologies. ... capability to support Steven Laffoon and his ... Niemann-Pick Disease Type A (NPA), a rare and fatal ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare ... conditions, announced today that it has closed the final ... raising a total of $5.175 million, which includes proceeds ... Josh Disbrow , Chief Executive Officer of ... to be used to conduct clinical studies for both ...
(Date:9/2/2015)... , September 2, 2015 ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, announced today that presentations highlighting ... will be delivered at the Ophthalmology Futures European ... Society of Cataract & Refractive Surgeons ("ESCRS"), both ...
Breaking Biology Technology:Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
Cached News: